Randall J. Lanham is General Counsel at NYMOX PHARMACEUTICAL CORP (NYMX). They have made 1 open-market trade across 1 company since 2018, most recently 2018-10-28.
CIK 0001278724
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $5K since 2018, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NYMX | 152,900 | $31K |
Shares reported on the most recent Form 4, priced at the 2018-11-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NYMX | BUY | 2018-10-28 | 2018-11-06 | $1.72 | $5K | -1.0% | -10.7% | +13.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.